Bristol-Myers Squibb (BMS) to Acquire Celgene for $74B

 Bristol-Myers Squibb (BMS) to Acquire Celgene for $74B

Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • BMS acquires Celgene, in all stock transaction for $74B. Celgene to receive $50/share,
    1 BMS share  and 1 Contingent Value Right (CVR) of $9 cash as regulatory milestone for each future approval of Celgene’s three drugs candidates ozanimod, liso-cel, bb2121
  • Celgene has received premium value of 54% on its last day closing share price making it  $102.43/share. The focus of the acquisition is to expand its portfolio in Oncology, Immunology and Inflammation and Cardiovascular Disease. The transaction is expected to close in Q3’19
  • Ozanimod is a P-III candidate indicated for relapsing multiple sclerosis and ulcerative colitis
    with its expected approval in 31 Dec, 2020. Lisocabtagene maraleucel (JCAR01, liso-cel) is a CD19-directed CAR T candidate indicated for r/r B cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma Grade 3B, and mantle cell lymphoma with expected approval in 31 Dec, 2020

Click here to read full press release/ article | Ref: BMS | Image: Record Journal

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at

Related post